Mary O’Neill

Small Molecule Antagonists of the σ-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth <b> <i>in Vitro</i> </b> and <b> <i>in Vivo</i> </b>

Barbara A. Spruce, Lorna Campbell, N. McTavish et al. · Cancer Research · 2004 · 165 citations

Usnic acid: a non-genotoxic compound with anti-cancer properties

Margareth Mayer, Mary O’Neill, Karen Murray et al. · Anti-Cancer Drugs · 2005 · 128 citations

Oncology, Biochemistry, Oncogenic Agent +13

Seliciclib (CYC202, R‐roscovitine) enhances the antitumor effect of doxorubicin <i>in vivo</i> in a breast cancer xenograft model

Maria Virginia C.L. Appleyard, Mary O’Neill, Karen Murray et al. · International Journal of Cancer · 2008 · 51 citations · Full text

Single Agent Doxorubicin, Mcf7 Xenografts, Breast Oncology +14

MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism

F. Paulin, Mary O’Neill, G. McGregor et al. · BMC Cancer · 2008 · 47 citations · Full text

The restriction–modification genes of <i>Escherichia coli</i> K-12 may not be selfish: They do not resist loss and are readily replaced by alleles conferring different specificities

Mary O’Neill, Angela Chen, Noreen E. Murray · Proceedings of the National Academy of Sciences · 1997 · 37 citations